Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at JPMorgan Healthcare Conference Transcript

Jan 10, 2022 / 02:45PM GMT
Release Date Price: R$65.55 (+0.21%)
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting a fireside chat this morning with Joaquin Duato, who's assuming the CEO role at J&J earlier this year. So Joaquin, Happy New Year, and great to be speaking with you today.

Maybe just to kick off the conversation, and I know this is your first presentation to The Street as CEO, would love to hear about your top priorities as you move into the role.

Joaquin Duato
Johnson & Johnson - CEO & Director

Thank you, Chris, and thank you, everybody, for joining. As you can imagine, I am deeply honored to be the eighth CEO of this remarkable company, Johnson & Johnson. And I am very excited about taking the role now in what I think is a moment of opportunity for health care in which Johnson & Johnson, it's in a very good position to continue to create value and accelerate growth by focusing mainly on what has made us great, differentiation based on science and technology.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot